Mark Lowdell

Mark Lowdell

Company: INmune Bio, Inc.

Job title: CSO


Arming Cell Therapies to Override Immunosuppressive Mechanisms & Penetrate Tumours 9:00 am

Priming patients NK cells with INKmune to initiate successful homing to the tumour microenvironment and elimination of cancer cells Reviewing preclinical data of “pseudokine” activity producing the same proteomic effects of combinations of IL12/15/18 Leveraging clinical data of the clinical responses of “pseudokine” to determine its safety and efficacyRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.